Home › Cytokinetics, Amgen drug shows promise in heart failure study
 

Keywords :   


Cytokinetics, Amgen drug shows promise in heart failure study

2015-11-09 05:29:58| Biotech - Topix.net

ORLANDO: An experimental heart failure drug being developed by Cytokinetics Inc and Amgen Inc demonstrated several beneficial cardiac function effects in a midstage clinical trial, according to data presented on Sunday. The trial of 448 patients with chronic heart failure already receiving optimal care tested a twice-a-day oral version of the drug, omecamtiv mecarbil, against a placebo over 20 weeks.

Tags: study shows heart drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06PPG to Announce Second-quarter 2024 Results July 18
26.06Fresh Coat for First Responders: New Hampshire Fire Station Gets a Makeover by California Paints
26.06Michigan Sets Record Recycling Rate in 2023, Recycles Nearly 70,000 Tons of Materials
26.06Companies Seek Federal EPR: How Producers Can Prepare
26.06Q&A with GFLs Tyler Stefure: Integrating New Fleet Tech & Upholding GFL Values
26.06SWANA Publishes Report on the Performance of Seattles Zero Waste System
26.06Baltimore Sues Major Brands for Alleged Role in Plastic Pollution Crisis
26.06Petco Aims Sight at Large-Scale Recycling Program to Divert LDPE Plastic from Landfills
More »